Arthrosi Therapeutics Surpasses 50% Patient Enrollment in Replicate Pivotal Phase 3 REDUCE 1 Trial of Pozdeutinurad (AR882) in Patients with Gout, Including Those with Tophaceous Gout
REDUCE 1 enrollment is well ahead of schedule; completion of enrollment expected in 2H 2025- REDUCE 1 is a study running in parallel with REDUCE 2 to evaluate pozdeutinurad's efficacy in lowering serum urate (sUA) levels and resolution of target tophi in gout patients – Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially […]